---

Immunotherapy in cancer: A review

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Suraksha C Kadam, Sainath M Nair, Yogesh A Jankar, Disha Sharma, Sandip G Badadhe, Minal R Ghante, Preeti D Kulkarni*

Volume : 7, Issue : 1, Year : 2022

Article Page : 27-29

https://doi.org/10.18231/j.ijcaap.2022.005

Suggest article by email

Get Permission

Abstract

Cancer is the most threatening disorder with increasing stuffers globally. Immune system of human body carries a set of defensive processes whenever cancer is detected by its specialized cells. While immunosurveillance, the host fight against foreign antigens. By targeting surface antigens expressed in tumor cells, monoclonal antibodies have demonstrated efficacy as cancer therapeutics. The checkpoint blockade therapy involves the use of antibodies to block pathways inhibiting the endogenous immune response to cancer. Adoptive cell transfer (ACT) is highly personalized cancer bearing host of immune cells with direct anticancer activity. We emphasize how the history of cancer immunotherapy paved the path for discoveries that are now standard of care in this review article.

Keywords: Chimeric antigen receptor (CAR) T cell therapy, Immune checkpoint inhibitors, Monoclonal antibodies, Therapeutic vaccines

How to cite : Kadam S C, Nair S M, Jankar Y A, Sharma D, Badadhe S G, Ghante M R, Kulkarni P D, Immunotherapy in cancer: A review. IP Int J Compr Adv Pharmacol 2022;7(1):27-29

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.